ASCO20: Adaptimmune updates work at T-cell frontier; SPEAR in high gear, ASCO hears June 1, 2020 By Randy Osborne No Comments Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) rocketed to $11.07 Friday, up $127% or $6.21, on updated data rolled out at the American Society of Clinical Oncology (ASCO) meeting, held virtually this year.Read More